Upadacitinib 30 mg tops JAK inhibitors for moderate-to-severe atopic dermatitis in network meta-analysisUpadacitinib Shows Highest Efficacy for Moderate to Severe Atopic Dermatitis

International journal of dermatology Published July 1, 2026 Study authors: Babul Arya, Mehta Devina, Soliman Yssra, Hussain Momina, Babul Najib PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider upadacitinib 30 mg as a high-efficacy option for moderate-to-severe atopic dermatitis based on indirect comparisons.

This systematic review and Bayesian network meta-analysis synthesized data from 9 randomized controlled trials involving 4261 adults with moderate-to-severe atopic dermatitis to compare the efficacy of four oral JAK inhibitors: upadacitinib (15/30 mg), abrocitinib (100/200 mg), baricitinib (2/4 mg), and ivarmacitinib (4/8 mg). The primary outcomes were EASI-75, IGA-AD 0/1, and Itch NRS reduction (≥4-point) at 12-16 weeks.

Upadacitinib 30 mg demonstrated the greatest efficacy across all primary outcomes. For EASI-75, the odds ratio was 12.3 (95% CrI 7.9-18.7); for IGA-AD 0/1, OR 18.9 (95% CrI 12.0-29.7); and for Itch NRS reduction, OR 11.1 (95% CrI 7.2-17.5). The treatment hierarchy (SUCRA) confirmed upadacitinib 30 mg as the top performer with scores of 97%-98%.

The authors note a key limitation: the lack of direct head-to-head randomized clinical trials comparing these agents. All efficacy estimates are derived from indirect comparisons. Safety data were not reported in this analysis.

These findings support a provisional efficacy preference for upadacitinib in managing moderate-to-severe atopic dermatitis unresponsive to biologic or topical therapies, but clinicians should interpret results cautiously given the indirect nature of the evidence.

How this fits prior evidence

This network meta-analysis extends prior coverage on atopic dermatitis by providing comparative efficacy data among oral JAK inhibitors, whereas earlier items focused on individual agents or adjunctive therapies. Specifically, it contrasts with the nemolizumab finding (which showed maintenance benefit) by addressing induction-phase efficacy. It also complements the vitamin D supplementation finding by offering a pharmacologic alternative for symptom management. The analysis addresses a gap in head-to-head comparisons, though direct trials remain lacking.

Researchers analyzed data from 4,261 adults with moderate to severe atopic dermatitis. They compared four different oral medications known as JAK inhibitors: upadacitinib, abrocitinib, baricitinib, and ivarmacitinib. The study looked at how well these drugs reduced skin symptoms and itching over a period of 12 to 16 weeks.

The analysis found that upadacitinib at a 30 mg dose showed the strongest results for improving skin scores and reducing itching compared to the other three medications. Specifically, it performed best in three main categories: overall skin improvement, clear skin scores, and significant reduction in itch levels.

It is important to note that this was a network meta-analysis, which combines data from several different trials rather than one direct head-to-head test between the drugs. Because there are no direct trials comparing these specific medications side by side, the results should be viewed as an estimate of how they compare. Talk to your doctor to see if these findings apply to your specific treatment plan.

What this means for you:

Upadacitinib showed the strongest results for skin clearance and itch relief among several JAK inhibitors studied.

Common questions

Which medication was most effective for skin symptoms?

The study found that upadacitinib at a 30 mg dose showed the greatest efficacy compared to abrocitinib, baricitinib, and ivarmacitinib. It performed best in measuring overall skin improvement (EASI-75) and achieving clear skin scores (IGA-AD 0/1).

How much did the medications help with itching?

Upadacitinib at a 30 mg dose was found to be the most effective for itch reduction. It showed a significant improvement in itch scores compared to the other three oral JAK inhibitors tested in this analysis.

Is this finding based on a direct head-to-head trial?

No, this was a network meta-analysis which combined data from 9 different trials. Because there are no direct head-to-head randomized clinical trials comparing these specific agents, the results represent an estimate of efficacy rather than a direct comparison.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedJul 2026

PMID41489415

View Original Abstract ↓

BACKGROUND: Janus kinase inhibitors (JAKis) have revolutionized the management of moderate-to-severe atopic dermatitis (AD). Although agents approved by the United States Food and Drug Administration (FDA), such as upadacitinib and abrocitinib, are widely used, and baricitinib and ivarmacitinib are under investigation, direct head-to-head randomized clinical trials (RCTs) comparing these agents are lacking. OBJECTIVE: Our aim was to rank the short-term efficacy of four oral JAKis, upadacitinib (15/30 mg), abrocitinib (100/200 mg), baricitinib (2/4 mg), and ivarmacitinib (4/8 mg), in moderate-to-severe AD using a Bayesian Network Meta-Analysis (BNMA). METHODS: Conducted per PRISMA 2020 guidelines and registered in PROSPERO (CRD420251116775), this study systematically reviewed phase 2 and 3 RCTs evaluating JAKi monotherapy in adults with moderate-to-severe AD. Primary endpoints included: (1) ≥ 75% improvement in Eczema Area and Severity Index (EASI-75), (2) Investigator's Global Assessment (IGA-AD 0/1), and (3) ≥ 4-point reduction in itch numeric rating scale (Itch NRS) at 12-16 weeks. Bayesian hierarchical modeling estimated odds ratios (ORs) with 95% credible intervals (CrIs), and surface under the cumulative ranking curve (SUCRA) probabilities defined the treatment hierarchy. RESULTS: Nine RCTs (n = 4261) were included. Upadacitinib 30 mg demonstrated the greatest efficacy across all endpoints, EASI-75 (OR = 12.3; 95% CrI 7.9-18.7), IGA-AD 0/1 (OR = 18.9; 95% CrI 12.0-29.7), and Itch NRS (OR = 11.1; 95% CrI 7.2-17.5), followed by upadacitinib 15 mg, abrocitinib 200 mg, and ivarmacitinib 8 mg. Baricitinib 2 mg and 4 mg consistently ranked lowest. SUCRA values confirmed upadacitinib 30 mg as the top performer (97%-98%). CONCLUSION: Among oral JAKis, upadacitinib 30 mg, followed by upadacitinib 15 mg, achieved the most consistent short-term efficacy, providing superior skin clearance and itch relief. Abrocitinib 200 mg and ivarmacitinib 8 mg showed intermediate benefits, whereas baricitinib displayed modest effects. These findings support a provisional efficacy preference for upadacitinib in managing moderate-to-severe AD unresponsive to biologic or topical therapies.

Upadacitinib 30 mg tops JAK inhibitors for moderate-to-severe atopic dermatitis in network meta-analysisUpadacitinib Shows Highest Efficacy for Moderate to Severe Atopic Dermatitis

How this fits prior evidence

Common questions

Study Details

Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment

Study checks how well pain scores track joint damage in psoriatic arthritis patients

Clinical research that matters. Delivered to your inbox.

Upadacitinib 30 mg tops JAK inhibitors for moderate-to-severe atopic dermatitis in network meta-analysisUpadacitinib Shows Highest Efficacy for Moderate to Severe Atopic Dermatitis

How this fits prior evidence

Common questions

More on Atopic Dermatitis

Study Details

Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment

Study checks how well pain scores track joint damage in psoriatic arthritis patients

Clinical research that matters. Delivered to your inbox.

Related in Dermatology

From Other Specialties